FIRST AMENDMENT TO THE AMENDED AND RESTATED LEAD DMD PRODUCT MANUFACTURING & SUPPLY AGREEMENTLead DMD Product Manufacturing & Supply Agreement • August 2nd, 2023 • Sarepta Therapeutics, Inc. • Pharmaceutical preparations
This first amendment to the Amended and Restated Lead DMD Product Manufacturing & Supply Agreement (“First Amendment”) by and between Sarepta Therapeutics Three, LLC (“Sarepta”), and Catalent Maryland, Inc. (“Catalent”).
= Identified information has been excluded from this exhibit because it is both (i) information that the Company customarily and actually treats as private or confidential and (ii) is not material AMENDED & RESTATED LEAD DMD PRODUCT MANUFACTURING &...Lead DMD Product Manufacturing & Supply Agreement • August 2nd, 2023 • Sarepta Therapeutics, Inc. • Pharmaceutical preparations • New York
SECOND AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT BETWEEN THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN’S HOSPITAL AND SAREPTA THERAPEUTICS THREE LLC (as successor to SAREPTA THERAPEUTICS, INC.)Exclusive License Agreement • August 2nd, 2023 • Sarepta Therapeutics, Inc. • Pharmaceutical preparations
This Second Amendment (“Second Amendment”) is entered into as of July 11, 2023 (“Second Amendment Date”), by and between the Research Institute at Nationwide Children’s Hospital (“Research Institute”) and Sarepta Therapeutics Three LLC (“Licensee”).
= Identified information has been excluded from this exhibit because it is both (i) information that the Company customarily and actually treats as private or confidential and (ii) is not material EXCLUSIVE LICENSE AGREEMENT BETWEEN THE RESEARCH...Exclusive License Agreement • August 2nd, 2023 • Sarepta Therapeutics, Inc. • Pharmaceutical preparations • Ohio
This Exclusive License Agreement (the “Agreement”) is entered into as of the last date of the signatures below (the “Effective Date”) by and between the Research Institute at Nationwide Children’s Hospital, 700 Children’s Drive, Columbus, OH 43205 (“Research Institute”) and Sarepta Therapeutics, Inc., a Delaware corporation having offices at 215 First Street, Cambridge, MA 02142 (“Licensee”).
